NCT04112316 - Developing Oral LT3 Therapy for Heart Failure - HFrEF | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions

Heart Failure With Reduced Ejection Fraction (HFrEF)Low T3 Syndrome

Interventions

DRUG

Liothyronine

Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose was 2.5 mcg three times daily and the maximum LT3 dose was 12.5 mcg three times daily.

OTHER

Placebo

A placebo tablet matching in appearance to LT3 tablets. Minimum placebo tablet dose was 1/2 tablet three times daily and the maximum placebo dose was 2 1/2 tablets three times daily.

Trial Locations (1)

19104

PennMedicine, Philadelphia

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Pennsylvania

OTHER